Verona Pharma has announced a successful initial launch of its chronic obstructive pulmonary disease (COPD) treatment, Ohtuvayre (ensifentrine), in the U.S. market during the third quarter of 2024. The company reported net sales of $5.6 million for Ohtuvayre in Q3, with October sales exceeding the previous quarter's figures, signaling increasing market adoption.
The launch has seen significant uptake, with over 5,000 prescriptions filled by more than 2,200 unique healthcare professionals. This broad acceptance suggests that Ohtuvayre is being utilized across various COPD patient types.
Verona Pharma is actively expanding its development pipeline. Two Phase 2 clinical trials are currently underway. One trial is evaluating a combination therapy of ensifentrine with glycopyrrolate for COPD maintenance. The other is investigating ensifentrine's potential in treating non-cystic fibrosis bronchiectasis. These trials reflect the company's commitment to further research and development in respiratory disease.
Despite the promising sales figures, Verona Pharma reported a net loss of $43 million for the quarter. This loss is attributed to increased research and development (R&D) and selling, general, and administrative (SG&A) expenses associated with the Ohtuvayre launch. However, the company maintains a strong cash position of $336 million, supported by strategic financing activities.
Management at Verona Pharma remains optimistic about the continued growth of Ohtuvayre sales and the progress of its clinical trials. These advancements are expected to strengthen the company's position in the respiratory treatment market.
